VVM
AKRO

Versant Venture Management’s Akero Therapeutics AKRO Stock Holding History

Versant Venture Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-617,727
Closed -$8.77M – 9
2022
Q1 		$8.77M Hold
617,727
– – 8.75% 5
2021
Q4 		$13.1M Hold
617,727
– – 6.99% 5
2021
Q3 		$13.8M Hold
617,727
– – 5.72% 6
2021
Q2 		$15.3M Hold
617,727
– – 5.08% 7
2021
Q1 		$17.9M Sell
617,727
-160,000
-21% -$4.84M 3.49% 7
2020
Q4 		$20.1M Hold
777,727
– – 2.08% 8
2020
Q3 		$23.9M Sell
777,727
-1,337,727
-63% -$46.8M 4.38% 6
2020
Q2 		$52.7M Sell
2,115,454
-621,118
-23% -$14.2M 7.57% 4
2020
Q1 		$58M Buy
+2,736,572
New +$58.7M 15.91% 3

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Versant Venture Management's AKRO Position: Q2 2022 in Review

Versant Venture Management sold out of Akero Therapeutics (AKRO) in Q2 2022, closing a stake of 617,727 shares — an estimated $8.77M sold.

Versant Venture Management first reported a position in AKRO in Q1 2020 and held it in 9 quarters. The position peaked at $58M in Q1 2020. 113 funds tracked by Wall St. Rank hold AKRO as of Q2 2022.

  • Versant Venture Management reported no remaining Akero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Versant Venture Management sold 617,727 Akero Therapeutics shares in Q2 2022, an estimated $8.77M.
  • Versant Venture Management first reported a position in Akero Therapeutics in Q1 2020 and held it in 9 quarters.
  • Versant Venture Management's Akero Therapeutics position peaked at $58M in Q1 2020.
  • 113 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2022.

Based on Versant Venture Management's 13F filing for Q2 2022, filed 11 Aug 2022.